UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2332-3
Program Prior Authorization/Medical Necessity
Medication *Entyvio® (vedolizumab)
*This program applies to the subcutaneous formulation of vedolizumab
P&T Approval Date 4/2024, 5/2024, 10/2024
Effective Date 1/1/2025
1. Background:
Entyvio (vedolizumab) for subcutaneous use is an integrin receptor antagonist indicated in adults for
the treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD).
2. Coverage Criteriaa:
A. Ulcerative Colitis
1. Initial Authorization
a. Entyvio for subcutaneous use will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active ulcerative colitis
-AND-
(2) One of the following:
(a) Patient has been established on therapy with Entyvio under an active
UnitedHealthcare medical benefit prior authorization for the treatment of
moderately to severely active ulcerative colitis
-OR-
(b) Both of the following:
i. Patient is currently on Entyvio for subcutaneous use therapy as documented by
claims history or submission of medical records (Document date and duration of
therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from a manufacturer sponsored
program (e.g., sample card which can be redeemed at a pharmacy for a free
supply of medication) as a means to establish as a current user of Entyvio*
-AND-
© 2024 UnitedHealthcare Services, Inc.
1
(3) Patient is not receiving Entyvio for subcutaneous use in combination with another
targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi
(golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Xeljanz (tofacitinib)]
-AND-
(4) Prescribed by or in consultation with a gastroenterologist
* Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from
a manufacturer sponsored program shall be required to meet initial authorization criteria as if
patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Entyvio for subcutaneous use will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Entyvio for subcutaneous use therapy
-AND-
(2) Patient is not receiving Entyvio for subcutaneous use in combination with another
targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi
(golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Xeljanz (tofacitinib)]
Authorization will be issued for 12 months.
B. Crohn’s Disease
1. Initial Authorization
a. Entyvio for subcutaneous use will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active Crohn’s disease
-AND-
(2) One of the following:
(a) Patient has been established on therapy with Entyvio under an active
UnitedHealthcare medical benefit prior authorization for the treatment of
moderately to severely active Crohn’s disease
-OR-
(b) Both of the following:
© 2024 UnitedHealthcare Services, Inc.
2
i. Patient is currently on Entyvio for subcutaneous use therapy as documented by
claims history or submission of medical records (Document date and duration of
therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from a manufacturer sponsored
program (e.g., sample card which can be redeemed at a pharmacy for a free
supply of medication) as a means to establish as a current user of Entyvio*
-AND-
(3) Patient is not receiving Entyvio for subcutaneous use in combination with another
targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi
(golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Xeljanz (tofacitinib)]
-AND-
(4) Prescribed by or in consultation with a gastroenterologist
* Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from
a manufacturer sponsored program shall be required to meet initial authorization criteria as if
patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Entyvio for subcutaneous use will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Entyvio for subcutaneous use therapy
-AND-
(2) Patient is not receiving Entyvio for subcutaneous use in combination with another
targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi
(golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Xeljanz (tofacitinib)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
© 2024 UnitedHealthcare Services, Inc.
3
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Entyvio [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; April 2024.
Program Prior Authorization/Medical Necessity – Entyvio (vedolizumab)
Change Control
4/2024 New program.
5/2024 Added coverage criteria for Crohn’s disease. Updated background and
reference.
10/2024 Updated coverage criteria for ulcerative colitis and Crohn’s disease.
© 2024 UnitedHealthcare Services, Inc.
4